• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Auris Medical secures $50M Series C financing for inner ear

Auris Medical secures $50M Series C financing for inner ear

April 17, 2013
CenterWatch Staff

Auris Medical, a Swiss biotechnology company focused on novel therapeutics for the treatment of inner ear disorders, has completed a $50 million Series C financing. Two leading venture capital firms, Sofinnova Ventures  of Menlo Park, Calif., and Sofinnova Partners of Paris, participated in the financing.

The funding will enable Auris Medical to advance its two clinical projects, AM-101 for the treatment of acute tinnitus and AM-111 for the treatment of acute inner ear hearing loss, through phase III studies and ultimately to market launch.

In connection with the fund raising, Jim Healy, MD, PhD, general partner at Sofinnova Ventures, and Antoine Papiernik, MBA, managing partner at Sofinnova Partners, joined Auris Medical's board of directors.

"The Series C financing represents an important milestone on our way to bring safe and effective therapies to the many patients suffering world-wide from tinnitus or hearing loss for whom today no proven drug-based treatment options exist,” said Thomas Meyer, founder and managing director of Auris Medical. "Having established proof of concept in phase IIb studies, we are now ready to move forward with our clinical development plans. Thanks to this latest financing round our leadership position in the emerging market for inner ear therapeutics will be further strengthened."

Healy said, "We are impressed with the significant clinical progress that Auris Medical has made towards developing first-in-class therapeutics for two inner ear disorders. We are pleased to bring our expertise and network to back Auris Medical's team and help them build a successful and global business."

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing